Last updated at 26 Jun 2024 04:36 AM
Director
DIN: 00270687
Dileep Himmatrao Shinde is currently associated with 2 companies as Director. They serve as a Director at ANKUR DRUGS AND PHARMA LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 00270687.Dileep Himmatrao Shinde has previously been associated with 2 companies in roles such as Director and Additional Director.Dileep Himmatrao Shinde is currently involved in 1 different role. Their most recent position is with BALKRISHNA PAPER MILLS LIMITED as a Director. The first company Dileep Himmatrao Shinde was appointed to as a director was ANKUR DRUGS AND PHARMA LIMITED. Dileep Himmatrao Shinde is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Dileep Himmatrao Shinde is currently associated with 2 companies as Director. They serve as a Director at ANKUR DRUGS AND PHARMA LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 00270687.Dileep Himmatrao Shinde has previously been associated with 2 companies in roles such as Director and Additional Director.Dileep Himmatrao Shinde is currently involved in 1 different role. Their most recent position is with BALKRISHNA PAPER MILLS LIMITED as a Director. The first company Dileep Himmatrao Shinde was appointed to as a director was ANKUR DRUGS AND PHARMA LIMITED. Dileep Himmatrao Shinde is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
2
Male
India
Gain instant access to verified contact details.
Current Companies (2)
Current LLPs (0)
Past Companies (2)
4y 3m 2y 2m Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| ANKUR DRUGS AND PHARMA LIMITED | Director | 31-Aug-2004 |
| BALKRISHNA PAPER MILLS LIMITED | Director | 09-Sep-2022 |